Lee et al. observed an elevation in the level of high-affinity EGFR ligands in KRAS-mutant CRC PDXs and GC1118 exerted better anti-tumor effects in these models than cetuximab, thereby highlighting its unique therapeutic implication [14]. Here, KRAS is linked to neoplasm.